POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°º°, »ùÇà À¯Çüº°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Point Of Care Drug Of Abuse Testing Market Size, Share & Trends Analysis Report By Product (Immunoassay Test Strips And Cassettes, Oral Fluid Testing Kits), By Sample Type, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1790317
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 136 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,374,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,782,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,597,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

POC(Point of Care) ¾à¹°³²¿ë(DOA) °Ë»ç ½ÃÀå °³¿ä

¼¼°èÀÇ POC ¾à¹°³²¿ë °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 10¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2033³â¿¡ CAGR 9.62%·Î ¼ºÀåÇϸç, 2033³â¿¡´Â 24¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Òº¯, Ÿ¾×, È£Èí, ¶¡ ±â¹Ý ŰƮ¸¦ Æ÷ÇÔÇÑ POC °Ë»ç´Â ½Ã·á äÃë ÇöÀå¿¡¼­ ºü¸¥ °á°ú¸¦ Á¦°øÇϹǷΠº¹ÀâÇÑ ½ÇÇè½Ç ÀÎÇÁ¶ó°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.

ÀÌ·¯ÇÑ ÅøÀº ÀÓ»ó ÇöÀå, µµ·Îº¯ ´Ü¼Ó, Çб³, ½ÉÁö¾î °¡Á¤¿¡¼­µµ äÅõǰí ÀÖÀ¸¸ç, Àü ¼¼°è¿¡¼­ °øÁß º¸°Ç ¹× ¾ÈÀü Àü·«ÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀº POC DOA °Ë»ç ÀåºñÀÇ Á¤È®µµ, ¼Óµµ, »ç¿ë ÆíÀǼºÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ¸é¿ª ºÐ¼® ±â¹Ý Å×½ºÆ® ½ºÆ®¸³, ÈÞ´ë¿ë ºÐ¼®±â, µðÁöÅÐ ¸®´õ±âÀÇ °³¹ß·Î ÃÖ¼ÒÇÑÀÇ ½Ã·á 󸮷Πºü¸¥ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. AI¿Í ¸Ó½Å·¯´×ÀÌ ÀϺΠ°Ë»ç Ç÷§Æû¿¡ ÅëÇյDZ⠽ÃÀÛÇÏ¿© °á°ú ÇØ¼®À» µ½°í ÀÛ¾÷ÀÚÀÇ ½Ç¼ö¸¦ ÁÙÀÌ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû »ùÇøµ ¹æ¹ýÀÎ °æ±¸¾× ¹× ¹ßÇÑ ±â¹Ý °Ë»ç µî ºñħ½ÀÀû »ùÇøµ ¹æ¹ýÀº »ç¿ëÀÚÀÇ ÄÄÇöóÀ̾𽺠¹× ÇÁ¶óÀ̹ö½Ã¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ »õ·Î¿î Àåºñ´Â ´ÙÁß ÆÐ³Î ¾à¹° °Ë»ç¸¦ Áö¿øÇÏ¿© ¿ÀÇÇ¿ÀÀ̵å, ´ë¸¶, ÄÚÄ«ÀÎ, ¾ÏÆäŸ¹Î, º¥Á¶µð¾ÆÁ¦ÇÉ µî ¿©·¯ ¹°ÁúÀ» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÀ±Þ½Ç, °æÂû, ÀçȰ¼¾ÅÍ µî ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤ÀÌ ÇʼöÀûÀΠȯ°æ¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Áø´Ü ±â¼úÀÇ ¼ÒÇüÈ­, ½º¸¶Æ®Æù°úÀÇ ÅëÇÕ ¹× ºí·çÅõ½º Áö¿ø µ¥ÀÌÅÍ ·Î±ëÀ» Æ÷ÇÔÇÑ ¿¬°á ±â´ÉÀÇ Çâ»óÀ¸·Î ÀÌ·¯ÇÑ ÅøÀº ´õ¿í Ä£¼÷ÇÏ°í »ç¿ëÇϱ⠽¬¿öÁ³À¸¸ç, Àü¹®°¡ ½ÃÀå°ú ¼ÒºñÀÚ ½ÃÀå ¸ðµÎ¿¡¼­ äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¤ºÎÀÇ ±ÔÁ¦¿Í Á÷Àå ¾ÈÀü¿¡ ´ëÇÑ ³ë·ÂÀº POC DOA °Ë»ç ½ÃÀå È®´ëÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹°ú °°Àº ±¹°¡¿¡¼­´Â ¿¬¹æÁ¤ºÎÀÇ Àǹ«·Î ±³Åë, Ç×°ø, ÀÇ·á µî ¾ÈÀüÀÌ Á߽õǴ »ê¾÷¿¡ ´ëÇÑ ¾à¹° °Ë»ç°¡ Àǹ«È­µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¾ç¼º °á°ú°¡ ³ª¿ÀÁö ¾Ê´Â ÇÑ °Ë»ç½Ç È®ÀÎÀÌ ÇÊ¿äÇÏÁö ¾Ê°í ½Å¼ÓÇÑ ¼±º°°Ë»ç¸¦ Á¦°øÇÏ´Â ÇöÀå °Ë»ç ŰƮ°¡ ³Î¸® »ç¿ëµÇ±â ½ÃÀÛÇß½À´Ï´Ù. ƯÈ÷ ´ë¸¶ »ç¿ëÀÌ ÇÕ¹ýÈ­µÈ °üÇұǿ¡¼­´Â °Å¸® ¾à¹° °Ë»ç ÇÁ·Î±×·¥, ƯÈ÷ Á¤È®Çϰí À̵¿ °¡´ÉÇÑ POC Àåºñ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Çб³ÀÇ ¾à¹° ¿¹¹æ ÇÁ·Î±×·¥À̳ª ±ºÀÇ Ã¤Åà °úÁ¤¿¡¼­ ¾à¹° »ç¿ëÀ» ¾ïÁ¦Çϰí Á¶±â¿¡ ¹ß°ßÇϱâ À§ÇØ ºü¸¥ ½ºÅ©¸®´× ¹æ¹ýÀ» µµÀÔÇÏ´Â °æ¿ì°¡ ´Ã°í ÀÖ½À´Ï´Ù. À¯·´°ú ¾Æ½Ã¾Æ ÀϺΠÁö¿ª¿¡¼­´Â Á÷Àå ¾ÈÀü ¹× µµÇÎ ¹æÁö °ü·Ã ¹ý±Ô°¡ ¹ßÀüÇϰí ÀÖÀ¸¸ç, º¸´Ù Æø³ÐÀº ½ÃÇàÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·¹ÀÓ¿öÅ©´Â °ø°øÀÇ ¾ÈÀüÀ» ÁõÁø½Ãų »Ó¸¸ ¾Æ´Ï¶ó ´Ù¾çÇÑ ºÐ»êÇü ȯ°æ¿¡¼­ ¹èÆ÷ÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ°í, ºñ¿ë È¿À²ÀûÀ̸ç, »ç¿ëÇϱ⠽¬¿î °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ²ÙÁØÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

ÇÁ¶óÀ̹ö½Ã, ÆíÀǼº, ÀÚ°¡ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö¸é¼­ ÀçÅà DOA °Ë»ç°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Å°Æ®´Â Ÿ¾×, ¼Òº¯, ¸ð¹ß »ùÇÃÀ» »ç¿ëÇÏ¿© °³ÀΠȯ°æ¿¡¼­ ÀڽŰú ŸÀÎÀ» °Ë»çÇÒ ¼ö ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº ¼ÒºñÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ¿ø°ÝÀ¸·Î °Ç°­À» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ãÀ¸¸é¼­ ÀÚ°¡ °Ë»ç ¸ðµ¨ÀÇ Ã¤ÅÃÀ» ´õ¿í °¡¼ÓÈ­Çß½À´Ï´Ù. ¿ø°ÝÀÇ·á ¼­ºñ½º´Â Áßµ¶ Ä¡·á³ª ÅëÁõ °ü¸®¸¦ ¹Þ´Â ȯÀÚµéÀ» À§ÇØ ÀÌ·¯ÇÑ Å°Æ®¸¦ µµÀÔÇÏ¿© Ä¡·áÀÇ ¿¬¼Ó¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : °³¿ä

Á¦3Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : »ùÇà À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : ±â¼úº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå POC(Point of Care) ¾à¹°³²¿ë °Ë»ç ½ÃÀå : Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦9Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Point Of Care Drug Of Abuse Testing Market Summary

The global point of care drug of abuse testing market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, growing at a CAGR of 9.62% from 2025 to 2033, due to increasing substance misuse worldwide and the urgent need for rapid, decentralized drug testing solutions. POC testing, which includes urine, saliva, breath, and sweat-based kits, provides rapid results at the site of sample collection, eliminating the need for complex lab infrastructure.

These tools are increasingly being adopted in clinical settings, roadside enforcement, schools, and even at home, making them a key component in public health and safety strategies globally. Technological advancements are significantly enhancing the accuracy, speed, and usability of POC DOA testing devices. The development of immunoassay-based test strips, portable analyzers, and digital readers enables fast results with minimal sample handling. AI and machine learning are beginning to integrate into some testing platforms, assisting in result interpretation and reducing operator error. Non-invasive sampling methods, such as oral fluid and sweat-based testing, are improving user compliance and privacy. In addition, newer devices now support multi-panel drug testing, enabling simultaneous detection of multiple substances such as opioids, cannabis, cocaine, amphetamines, and benzodiazepines. These innovations are crucial in settings where quick decision-making is essential-such as emergency departments, law enforcement operations, and rehabilitation centers. The miniaturization of diagnostic technology and improved connectivity features, including smartphone integration and Bluetooth-enabled data logging, are making these tools more accessible and user-friendly, driving adoption in both professional and consumer markets.

Government regulations and workplace safety initiatives are key drivers in the expansion of the POC DOA testing market. In countries such as the U.S., federal mandates require drug screening for safety-sensitive industries such as transportation, aviation, and healthcare. This has led to widespread use of on-site testing kits that provide rapid screening without needing laboratory confirmation unless a positive result arises. Roadside drug testing programs, particularly in jurisdictions with legalized cannabis use, are also boosting demand for accurate and mobile POC devices. Moreover, school drug prevention programs and military recruitment processes increasingly incorporate quick screening methods to deter and identify drug use early. In Europe and parts of Asia, evolving workplace safety laws and anti-doping initiatives are supporting broader implementation. These frameworks not only promote public safety but also create a steady demand for reliable, cost-effective, and easy-to-use testing solutions that can be deployed in a range of decentralized environments.

The growing demand for privacy, convenience, and self-monitoring has led to a significant rise in at-home DOA testing. These kits allow individuals to test themselves or others in private settings using saliva, urine, or hair samples. The COVID-19 pandemic further accelerated the adoption of self-testing models, as consumers and healthcare providers looked for ways to monitor health remotely. Telehealth services have incorporated these kits for patients undergoing addiction treatment or pain management, enhancing continuity of care.

Global Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care drug of abuse testing market based on product, technology, sample type, end use, and region:

Table of Contents

Chapter 1. Point of Care Drug of Abuse (DOA) Testing Market: Methodology and Scope

Chapter 2. Point of Care Drug of Abuse (DOA) Testing Market: Executive Summary

Chapter 3. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

Chapter 4. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

Chapter 5. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

Chapter 6. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

Chapter 7. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

Chapter 8. Point of Care Drug of Abuse (DOA) Testing Market: Regional Business Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â